Drugs reducing cholesterol and abnormal lipid levels (lovastatin, fenofibrate, lomitapide, pravastatin, atorvastatin), as well as anti-hypertensive drugs (methyldopa, furosemide, warfarin), interact with hub genes of fatty acid transporters (APOB, APOA1, MTTP) and the DPP4 gene, associated with type 2 diabetes mellitus (Röhrborn 2015). Here, APOB is linked to type 2 diabetes mellitus.